AGIO vs. CTLT, ELAN, ROIV, INSM, LEGN, ASND, CERE, ITCI, JAZZ, and BPMC
Should you be buying Agios Pharmaceuticals stock or one of its competitors? The main competitors of Agios Pharmaceuticals include Catalent (CTLT), Elanco Animal Health (ELAN), Roivant Sciences (ROIV), Insmed (INSM), Legend Biotech (LEGN), Ascendis Pharma A/S (ASND), Cerevel Therapeutics (CERE), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry.
Agios Pharmaceuticals (NASDAQ:AGIO) and Catalent (NYSE:CTLT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, media sentiment, analyst recommendations, community ranking, valuation, dividends, risk and institutional ownership.
Catalent has a net margin of -26.61% compared to Agios Pharmaceuticals' net margin of -1,199.26%. Catalent's return on equity of -2.73% beat Agios Pharmaceuticals' return on equity.
Agios Pharmaceuticals presently has a consensus target price of $45.33, indicating a potential downside of 4.78%. Catalent has a consensus target price of $53.14, indicating a potential downside of 5.77%. Given Agios Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Agios Pharmaceuticals is more favorable than Catalent.
In the previous week, Agios Pharmaceuticals had 13 more articles in the media than Catalent. MarketBeat recorded 24 mentions for Agios Pharmaceuticals and 11 mentions for Catalent. Catalent's average media sentiment score of 1.09 beat Agios Pharmaceuticals' score of 0.79 indicating that Catalent is being referred to more favorably in the news media.
Catalent has higher revenue and earnings than Agios Pharmaceuticals. Catalent is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Catalent received 161 more outperform votes than Agios Pharmaceuticals when rated by MarketBeat users. However, 67.46% of users gave Agios Pharmaceuticals an outperform vote while only 59.10% of users gave Catalent an outperform vote.
Agios Pharmaceuticals has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500. Comparatively, Catalent has a beta of 1.2, indicating that its share price is 20% more volatile than the S&P 500.
Summary
Catalent beats Agios Pharmaceuticals on 10 of the 16 factors compared between the two stocks.
Get Agios Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AGIO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Agios Pharmaceuticals Competitors List
Related Companies and Tools
